Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Serbia

Research and Innovation Action · Running

STRATIFYHF Artificial intelligence-based decision support system for risk stratification and early detection of heart failure in primary and secondary care

Coordinator
Istrazivacko Razvojni Centar Za Bioinzenjering Bioirc Doo, Serbia
Runs
1 June 2023 to 31 May 2027
Status
Running
EU funding
€4.5m
Total cost
€4.5m
Partners
19 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101080905

What the project is doing

In the project's own words, from its summary on CORDIS.

Heart failure (HF) is a pandemic currently affecting up to 15 million people in Europe. It is a complex clinical syndrome presenting with impaired heart function and is associated with poor quality of life for patients and high healthcare costs. There is a high clinical demand for novel artificial intelligence (AI) tools which will facilitate risk stratification, early diagnosis, and disease progression assessment in HF.

Such tools are essential to allow prompt initiation of evidence-based prevention and treatment strategies which will improve patient quality of life, reduce morbidity and mortality and the HF burden on healthcare. STRATIFYHF aims to develop, validate and implement the first AI-based, decision support system (DSS) for risk stratification, early diagnosis, and disease progression assessment in HF to accommodate both primary and secondary care clinical needs.

The DSS will integrate patient-specific demographic and clinical data using existing and novel technologies and establish AI-based tools for risk stratification and HF prediction using machine learning. Additionally, a mobile app will be developed to empower patients to better manage their condition, and health care professionals to make informed decision in selection of evidence-based HF prevention and treatment strategies.

Our multidisciplinary consortium, including three small-to-medium enterprises (SMEs) and two stakeholder organisations, will be guided by medical advice and regulatory and health technology experts to deliver the DSS as a medical class 2b device, reaching TRL 8 by the end of the project. STARTIFYHF will change the way in which HF is diagnosed today and thereby improve the quality and length of patients’ lives and lead to efficient and sustainable healthcare systems by reducing the number of HF-related hospital admissions and unnecessary referrals from primary to secondary care in Europe and beyond.

Topics

Who is involved

OrganisationCityCountryRole
Istrazivacko Razvojni Centar Za Bioinzenjering Bioirc DooKragujevacSerbiaCoordinator
Pknm Solutions SARLColombierSwitzerlandAssociatedpartner
Klinikum Der Universitaet RegensburgRegensburgGermanyParticipant
Idryma Technologias Kai ErevnasIrakleioGreeceParticipant
Bcn Health Economics & Outcomes Research SLBarcelonaSpainParticipant
Servicio Madrileno De SaludMadridSpainParticipant
Azienda Ospedaliero-Universitaria CareggiFirenzeItalyThird party
Azienda Unita' Sanitaria Locale Toscana CentroFirenzeItalyThird party
Universita Degli Studi Di FirenzeFlorenceItalyParticipant
Gpcardio BVHaarlemNetherlandsParticipant
Medcon International BVHeemstedeNetherlandsParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Institut Za Kardiovaskularne Bolesti VojvodineSremska KamenicaSerbiaThird party
Udruzenje Za Srcanu Slabost SrbijeBelgradeSerbiaParticipant
University of Novi Sad, Faculty of Medicine Novi SadNovi SadSerbiaParticipant
Univerza V LjubljaniLjubljanaSloveniaParticipant
Coventry UniversityCoventryUnited KingdomAssociatedpartner
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomAssociatedpartner
University of Newcastle Upon TyneNewcastle Upon TyneUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI